{"id":"ro4917838","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1171829","moleculeType":"Small molecule","molecularWeight":"543.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CDK9 is a crucial component of the positive transcription elongation factor b (P-TEFb) complex, which is involved in the regulation of RNA polymerase II-mediated transcription. By inhibiting CDK9, RO4917838 aims to reduce the expression of genes involved in cancer cell proliferation and survival.","oneSentence":"RO4917838 is a small molecule that targets the CDK9 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:33.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT06910358","phase":"PHASE3","title":"Study of Bitopertin in Participants With EPP or XLP (APOLLO)","status":"RECRUITING","sponsor":"Disc Medicine, Inc","startDate":"2025-04-04","conditions":"Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)","enrollment":150},{"nctId":"NCT05308472","phase":"PHASE2","title":"Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP","status":"COMPLETED","sponsor":"Disc Medicine, Inc","startDate":"2022-10-31","conditions":"Erythropoietic Protoporphyria","enrollment":75},{"nctId":"NCT05883748","phase":"PHASE2, PHASE3","title":"HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP","status":"ENROLLING_BY_INVITATION","sponsor":"Disc Medicine, Inc","startDate":"2023-08-31","conditions":"Erythropoietic Protoporphyria","enrollment":230},{"nctId":"NCT03271541","phase":"PHASE2","title":"A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-26","conditions":"Beta-Thalassemia","enrollment":12},{"nctId":"NCT01674361","phase":"PHASE2","title":"A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-12-31","conditions":"Obsessive-Compulsive Disorder","enrollment":99},{"nctId":"NCT01192867","phase":"PHASE3","title":"A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-12-11","conditions":"Schizophrenia","enrollment":629},{"nctId":"NCT01543529","phase":"PHASE1","title":"A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02-28","conditions":"Healthy Volunteer","enrollment":25},{"nctId":"NCT01192880","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-11","conditions":"Schizophrenia","enrollment":625},{"nctId":"NCT01235559","phase":"PHASE3","title":"A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-12","conditions":"Schizophrenia","enrollment":604},{"nctId":"NCT01116830","phase":"PHASE1","title":"A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-11","conditions":"Schizophrenia","enrollment":29},{"nctId":"NCT01356550","phase":"PHASE1","title":"A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-06","conditions":"Healthy Volunteer","enrollment":35},{"nctId":"NCT01192906","phase":"PHASE3","title":"A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-12","conditions":"Schizophrenia","enrollment":624},{"nctId":"NCT01613040","phase":"PHASE1","title":"A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-01","conditions":"Healthy Volunteer","enrollment":169},{"nctId":"NCT01510899","phase":"PHASE1","title":"A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-10","conditions":"Healthy Volunteer","enrollment":12},{"nctId":"NCT01495104","phase":"PHASE1","title":"A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-10","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT01665976","phase":"PHASE1","title":"A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-08","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT01365403","phase":"PHASE1","title":"A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT01438749","phase":"PHASE1","title":"A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-10","conditions":"Healthy Volunteer","enrollment":177},{"nctId":"NCT01235585","phase":"PHASE3","title":"A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-12","conditions":"Schizophrenia","enrollment":597},{"nctId":"NCT01433575","phase":"PHASE1","title":"A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT01636492","phase":"PHASE1","title":"A Study of Bitopertin (RO4917838) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-11","conditions":"Healthy Volunteer","enrollment":71},{"nctId":"NCT01183585","phase":"PHASE1","title":"A Study of RO4917838 With Rosuvastatin in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT01234779","phase":"PHASE2","title":"A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Schizophrenia","enrollment":301},{"nctId":"NCT01235520","phase":"PHASE3","title":"A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Schizophrenia","enrollment":595},{"nctId":"NCT00616798","phase":"PHASE2","title":"A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03","conditions":"Schizophrenia","enrollment":323}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RO4917838","genericName":"RO4917838","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RO4917838 is a small molecule that targets the CDK9 protein. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}